Search Our Pipeline Enabled by our proprietary drug discovery platform, we have developed a diverse pipeline of wholly-owned drug candidates.⁽¹⁾ Pipeline graphic is not for promotional use. Ripretinib APPROVED Broad Spectrum Inhibitor of KIT & PDGFRA Ripretinib is an orally administered switch-control kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop. GIST ≥4ᵗʰ Line (INVICTUS Study)⁽¹⁾ Approved LEARN MORE Vimseltinib PHASE 1/2 Inhibitor of CSF1R Vimseltinib is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor designed to selectively bind to the CSF1R switch pocket. Tenosynovial Giant Cell Tumor (TGCT) Phase 1/2 LEARN MORE DCC-3116 PHASE 1 Inhibitor of ULK DCC-3116 is an investigational, orally administered, potent and highly selective switch-control inhibitor of ULK kinase. RAS/RAF Mutant Cancers in Combination with Trametinib Phase 1 LEARN MORE Additional Programs PRE-CLINICAL Undisclosed LEARN MORE Updated as of May 2021; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK. twitter linkedin CONTACT US Main navigation Discovery Platform Pipeline Ripretinib Vimseltinib DCC-3116 Preclinical Pipeline Expanded Access Our Medicine QINLOCK® (ripretinib) Who We Are Management Board of Directors Join Us Open Positions Footer Utility Contact Us Terms of Use Privacy Policy Recruiting Privacy Policy Web Accessibility Statement © 2021 Deciphera Pharmaceuticals, Inc. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.